Arief S. Gunawan, Donal P. McLornan, Bridget Wilkins, Katherine Waghorn, Yvette Hoade, Nicholas C. P. Cross, Claire N. Harrison. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. Haematologica 2017;102(6):e238-e240; https://doi.org/10.3324/haematol.2017.163790.